Table 4.

Logistic regression analysis of tumor response to sorafenib and variables

Variables	Odds ratio	95% CI	p value
mTOR_VEGFR2_c-KIT_c-RAF (low vs. high)	15.93	3.18–79.73	0.002
Age (<55 vs. ≥55 years)	1.44	0.35–5.93	0.611
Gender (male vs. female)	1.83	0.44–7.62	0.404
HBV (absence vs. presence)	Inf.	0.00–Inf.	0.993
HCV (absence vs. presence)	0.00	0.00–Inf.	0.994
TNM stage (II–III vs. IV)	0.82	0.16–4.11	0.812
BCLC stage (AB vs. CD)	0.50	0.10–2.52	0.399
AFP level (<100 vs. ≥100 ng/mL)	0.52	0.12–2.21	0.373

CI, confidence interval; mTOR, mammalian target of rapamycin; VEGFR2, vascular endothelial growth factor receptor 2; c-KIT, KIT proto-oncogene receptor tyrosine kinase; c-RAF, Raf-1 proto-oncogene serine/threonine kinase; HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, Tumor, Node, and Metastasis classification; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein.